Bristol-Myers advancing HIV drugs after mid-stage successes
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb reported clinical trial data for two new HIV therapies on 25 and 26 February that support moving BMS-663068 and BMS-955176 into Phase III and Phase IIb trials.